| Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 11251354 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Revascularization procedures and particularly percutaneous transluminal coronary angioplasty are being performed more and more often in patients with unstable coronary artery disease, despite the fact that these procedures are known to carry a higher risk in such patients than in those with stable disease. This article reviews studies that have investigated the potential of modern antithrombotic therapy -- low-molecular-weight heparin, anti-Xa agents, direct antithrombin inhibitors and glycoprotein IIb/IIIa inhibitors -- to reduce the post-procedural event rate in such patients. The results are promising. |
| | |
Authors:
|
J P Bassand |
Related Documents
:
|
8730644 - Is aspirin, as used for antithrombosis, an emotion-modulating agent? 8950124 - Ancrod: the use of snake venom in the treatment of patients with heparin-induced thromb... 14551514 - The management of unstable angina and non-st-segment elevation myocardial infartion. 16816444 - Desensitization for the management of clopidogrel hypersensitivity: initial clinical ex... 9873904 - Motion and deformation tracking for short-axis echo-planar myocardial perfusion imaging. 10716134 - Left ventricular function and autonomic nervous system balance during two different sta... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Haemostasis Volume: 30 Suppl 2 ISSN: 0301-0147 ISO Abbreviation: Haemostasis Publication Date: 2000 |
Date Detail:
|
Created Date: 2001-03-19 Completed Date: 2001-07-05 Revised Date: 2009-02-07 |
Medline Journal Info:
|
Nlm Unique ID: 0371574 Medline TA: Haemostasis Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 114-21; discussion 106-7 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 S. Karger AG, Basel |
Affiliation:
|
Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France. jean-pierre.bassand@ufc-chu.univ-fcomte.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina, Unstable
/
complications,
drug therapy*,
mortality,
surgery Angioplasty, Transluminal, Percutaneous Coronary Antibodies, Monoclonal / therapeutic use Anticoagulants / administration & dosage, therapeutic use* Aspirin / administration & dosage, therapeutic use Clinical Trials as Topic Combined Modality Therapy Diabetes Complications Drug Therapy, Combination Factor Xa / antagonists & inhibitors Heparin, Low-Molecular-Weight / administration & dosage, therapeutic use* Hirudin Therapy Hirudins / administration & dosage, analogs & derivatives Humans Immunoglobulin Fab Fragments / therapeutic use Myocardial Revascularization* Oligosaccharides / administration & dosage, therapeutic use Peptide Fragments / administration & dosage, therapeutic use Peptides / therapeutic use Platelet Aggregation Inhibitors / administration & dosage, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Postoperative Complications / prevention & control Randomized Controlled Trials as Topic Recombinant Proteins / administration & dosage, therapeutic use Risk Factors Thrombocytopenia / chemically induced Thrombosis / prevention & control* Time Factors Treatment Outcome Tyrosine / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/Hirudins; 0/Immunoglobulin Fab Fragments; 0/Oligosaccharides; 0/PENTA; 0/Peptide Fragments; 0/Peptides; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 0/eptifibatide; 128270-60-0/bivalirudin; 143653-53-6/abciximab; 144494-65-5/tirofiban; 50-78-2/Aspirin; 55520-40-6/Tyrosine; EC 3.4.21.6/Factor Xa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery dis...
Next Document: Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical t...